HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

491.415

-11.982-2.38%

Number of Gainers:6

Number of Losers:24

Number of Flat:3

PE:- -

High:505.901

Open:503.516

Low:489.953

Close:503.398

Volume:44.20M

Turnover:1.61B

Market Cap:313.90B

Float Cap:277.80B

Loading ...

HBM Holdings Names CFO Youchen Chen Executive Director Amid Board Changes

Hbm Holdings - Yiping Rong Resigns as Executive Director Effective August 27, 2026

THOMSON REUTERS

Harbour Biomed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy

THOMSON REUTERS

Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy

Alphamab Oncology Swings to FY26 H1 Loss of RMB 40.46 Million; Revenue Falls 15.09% to RMB 271.24 Million

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million

Hbm Holdings H1 Revenue USD 122.5 Million

THOMSON REUTERS

Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion

TYK MEDICINES-B Secures Conditional NMPA Approval for Its Novel EGFR-TKI Therapy

Great-Sun Foods Posts 250% Surge in Total Profit as Pharmaceutical Arm Begins Consolidation

Cstone Pharma-B Reports Interim Results with Revenue Surging 314.75% to RMB 205 Million

China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales

CStone Pharmaceuticals - no Dividends Paid, Declared or Proposed During Interim Period

THOMSON REUTERS

CStone 1H FY26 Loss Narrows to RMB 252.28 Million; Revenue Rises to RMB 205.1 Million

CStone Pharmaceuticals H1 Revenue RMB 205.1 Million

THOMSON REUTERS

ZYLOXTB (02190) Spends HK$1.18 Million on Share Buyback on August 27

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Buyback Held as Treasury Shares at HKD 21.58-22.06

Healthcare Sector Set for Selective Gains in Second Half, Says Great Wall Fund Manager

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

JW (Cayman) Therapeutics H1 Net Income Attributable RMB -50.4 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BK1574/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":491.41547,"timestamp":1788235199005,"preClose":503.39795,"halted":0,"volume":44203396,"delay":0,"changeRate":-0.023803,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Noon Closed","change":-11.982483,"latestTime":"09-01 12:00:00","open":503.51608,"high":505.9005,"low":489.95316,"amount":1611248503,"amplitude":0.031679,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788238800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"pbRate":3.790203,"peRate":127.340212,"turnoverRate":0.001682,"increases":6,"decrements":24,"flats":2,"marketCap":313903329104,"floatMarketCap":277800815864},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":505.9005,"amplitude":0.031679,"preClose":503.39795,"low":489.95316,"pbRate":"3.790203","latestPrice":491.41547,"volume":44203396,"delay":0,"open":503.51608,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.773,"twentyDayClose":475.248,"sixtyDayClose":459.637,"secType":"PLATE","market":"HK","turnoverRate":0.001682,"peRate":127.340212,"marketCap":313903329104,"floatMarketCap":277800815864,"timestamp":1788235199005,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":24,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662085817","title":"HBM Holdings Names CFO Youchen Chen Executive Director Amid Board Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085817","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085817?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:07","pubTimestamp":1787839667,"startTime":"0","endTime":"0","summary":"HBM Holdings names CFO Youchen Chen executive director amid board changesHBM Holdings named CFO Youchen Chen and legal chief Ian Yi Liu as executive directors, effective Aug. 27, 2026.Executive direct","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL58VqTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1189","BK1518","BK1574","02158","BK1583","BK1161","00656","BK1617","BK1230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662899085","title":"Hbm Holdings - Yiping Rong Resigns as Executive Director Effective August 27, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662899085","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662899085?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:07","pubTimestamp":1787839630,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1HP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662021083","title":"Harbour Biomed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662021083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662021083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:05","pubTimestamp":1787839502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA91JKGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085166","title":"Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085166","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085166?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:05","pubTimestamp":1787839500,"startTime":"0","endTime":"0","summary":"established out-licensing agreements for innovative products, and strong. -- Profit for the period reached US$64.9 million, and adjusted net profit. for the period[1] was approximately US$71.6 million, marking seven","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","R","BK4022","CNS","BK1583","BK1574","MSS","AAQC","BK4232","BK4113","BK4135","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662608309","title":"Alphamab Oncology Swings to FY26 H1 Loss of RMB 40.46 Million; Revenue Falls 15.09% to RMB 271.24 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662608309","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662608309?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:03","pubTimestamp":1787839411,"startTime":"0","endTime":"0","summary":"Alphamab Oncology swings to FY26 H1 loss of RMB 40.46 million; revenue falls 15.09% to RMB 271.24 millionAlphamab Oncology posted a loss of RMB 40.46 million, swinging from a profit of RMB 21.58 milli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL6fG19l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084083","title":"HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084083","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:01","pubTimestamp":1787839287,"startTime":"0","endTime":"0","summary":"HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionHBM Holdings posted revenue of US$122.49 million for the six months ended June 30, 2026, up 20.9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL77D5HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BIB","BK4533","LU0109394709.USD","BK1161","BK1574","LU1983299246.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU2089984988.USD","LU2242646821.SGD","LU0058720904.USD","LU0122379950.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","BK4139","IE00BFTCPJ56.SGD","AMGN","BK4566","IE0002141913.USD","LU1571399168.USD","LU2468319806.SGD","BK4599","TBXU","PJP","LU1061106388.HKD","LU0889565916.HKD","LU2242652126.USD","BK4581","PBE","LU0289739699.SGD","IBBQ","IBB","LU0320765992.SGD","02142","IE00B2B36J28.USD","BK1583","LU1057294990.SGD","LU2112291526.USD","LU0868494617.USD","BK4585","BK4534","BBH","SG9999001440.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662083779","title":"Hbm Holdings H1 Revenue USD 122.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662083779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662083779?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:01","pubTimestamp":1787839260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLX0KDRVX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662790083","title":"Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790083","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662790083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:00","pubTimestamp":1787839249,"startTime":"0","endTime":"0","summary":"Akeso FY26 H1 net loss narrows 23.98% to RMB 447.2 million; revenue rises 27.92% to RMB 1.81 billionAkeso posted revenue of RMB 1.81 billion, up 27.92% year over year, driven mainly by cadonilimab and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL34jFkn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU1961090484.USD","LU2476274720.SGD","LU0348783233.USD","LU1720050803.USD","LU0348784397.USD","LU0348735423.USD","LU1794554557.SGD","IE00BPRC5H50.USD","LU0348766576.USD","LU0417516738.SGD","KURE","LU0348825331.USD","LU2399975544.HKD","BK1574","LU2488822045.USD","BK1161","LU0540923850.HKD","LU0348767384.USD","LU2778985437.USD","LU0348827113.USD","LU0634319403.HKD","LU0417516902.SGD","09926","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191561333","title":"TYK MEDICINES-B Secures Conditional NMPA Approval for Its Novel EGFR-TKI Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1191561333","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191561333?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:26","pubTimestamp":1787837163,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) has announced that its independently developed next-generation EGFR-TKI innovative drug, Duxenaitinib Mesylate Tablets (TY-9591), has received conditional marketing approval...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1574","09939","BK1161","IPOS","BK1515","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167119384","title":"Great-Sun Foods Posts 250% Surge in Total Profit as Pharmaceutical Arm Begins Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=1167119384","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167119384?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:22","pubTimestamp":1787833347,"startTime":"0","endTime":"0","summary":"Great-Sun Foods Co.,Ltd. (603336.SH) released its 2026 semi-annual report on the evening of August 27. Despite short-term pressure in its core fruit and vegetable business due to industry cycles, the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159938","BK0238","BK1161","603336","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146657120","title":"Cstone Pharma-B Reports Interim Results with Revenue Surging 314.75% to RMB 205 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1146657120","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146657120?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:42","pubTimestamp":1787830948,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) has released its interim results for the six months ended June 30, 2026, showing a substantial revenue increase of 314.75% to RMB 205 million. The company reported a loss of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662046377","title":"China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662046377","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662046377?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:40","pubTimestamp":1787830849,"startTime":"0","endTime":"0","summary":"China's CStone Pharmaceuticals H1 revenue soars on drug salesOverviewChina biopharma firm's half-year revenue rose 315% yr/yr to RMB205.1 mlnRevenue growth driven by higher pharmaceutical sales, espec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0IS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK0216","688796","LU0502904849.HKD","01801","03692","LU2242644610.SGD","LU2097828474.EUR","HK0000165453.HKD","LU0244354667.USD","LU2097828714.EUR","BK1589","LU1188198961.HKD","LU2097828631.EUR","LU2488822045.USD","BK1574","LU0455707207.USD","LU0463099449.HKD","LU2097828557.USD","BK1161","LU2097828805.USD","LU2328871848.SGD","LU1969619763.USD","LU0326950275.SGD","BK1191","KURE","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662885704","title":"CStone Pharmaceuticals - no Dividends Paid, Declared or Proposed During Interim Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2662885704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662885704?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:34","pubTimestamp":1787830486,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0WN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662701081","title":"CStone 1H FY26 Loss Narrows to RMB 252.28 Million; Revenue Rises to RMB 205.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662701081","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662701081?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:32","pubTimestamp":1787830367,"startTime":"0","endTime":"0","summary":"CStone 1H FY26 loss narrows to RMB 252.28 million; revenue rises to RMB 205.1 millionCStone Pharmaceuticals posted revenue of RMB 205.1 million, more than doubled year over year, driven by higher phar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL1Qdlyp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662701706","title":"CStone Pharmaceuticals H1 Revenue RMB 205.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662701706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662701706?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:32","pubTimestamp":1787830340,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLX88HRFB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138575619","title":"ZYLOXTB (02190) Spends HK$1.18 Million on Share Buyback on August 27","url":"https://stock-news.laohu8.com/highlight/detail?id=1138575619","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138575619?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:59","pubTimestamp":1787828381,"startTime":"0","endTime":"0","summary":"ZYLOXTB (02190) has announced that it repurchased 54,000 of its own shares on August 27, 2026.The transaction, which involved a total outlay of approximately HK$1.1829 million, was conducted as part...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02190","BK1583","BK1587","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706291","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Buyback Held as Treasury Shares at HKD 21.58-22.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706291","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662706291?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:50","pubTimestamp":1787827846,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return on share buyback held as treasury shares at HKD 21.58-22.06Zylox-Tonbridge bought back 54,000 H shares on Aug. 27, holding them as treasury shares","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL9nj6GH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1100","BK1587","02190"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101395901","title":"Healthcare Sector Set for Selective Gains in Second Half, Says Great Wall Fund Manager","url":"https://stock-news.laohu8.com/highlight/detail?id=1101395901","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101395901?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:41","pubTimestamp":1787827277,"startTime":"0","endTime":"0","summary":"After a period of correction and consolidation, the healthcare sector has shown robust performance over the past two months, with the once-prominent \"golden track\" seemingly returning to mainstream...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","159938","159992","IBBQ","LNGR","BK1574","BK1515","BK1161","MEDX","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708043","title":"China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708043","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708043?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:08","pubTimestamp":1787825320,"startTime":"0","endTime":"0","summary":"China's JW Therapeutics interim revenue rises 4.7% on Carteyva salesOverviewChina cell immunotherapy developer's interim revenue grew 4.7% yr/yr, driven by Carteyva salesGross profit margin improved t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1188198961.HKD","02126","LU0310799852.SGD","GLAM","IBB","PPH","01801","LU0949170772.SGD","IE0004445239.USD","IXJ","LU0868494617.USD","LU2362541513.USD","LU1934455863.HKD","JDOC","IE00BN8TJ469.HKD","LU0708994859.HKD","LU2237443382.USD","XLV","LU0859254822.USD","ABBV","REGN","IBBQ","LU0395794307.EUR","LU0463099449.HKD","RXL","LU1934455277.USD","CMI","FTXH","TBXU","IYH","TRUH","688331","LU0432979614.USD","MEDX","LU2237443978.SGD","VHT","LU1244550577.SGD","03692","IE00BVYPNV92.GBP","PJP","IE000SO60NU8.SGD","LU1037948897.HKD","LU2097828714.EUR","BBH","LU0943347566.SGD","BK1574","AGNG","FHLC","MADE","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708313","title":"JW (Cayman) Therapeutics H1 Net Income Attributable RMB -50.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708313","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708313?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:59","pubTimestamp":1787824747,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLXX950BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","BK1161","02126"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":6,"totalSize":383,"code":"91000000","status":"200"}]}}